The Food and Drug Administration on Friday approved a lower-cost version of the world’s top-selling drug, but don’t expect to see it at the pharmacy any time soon.
Biotech giant Amgen won FDA approval for its version of Humira, an anti-inflammatory treatment from AbbVie that brought in $14 billion in revenue last year. Amgen’s injection, called Amjevita, is a biosimilar of Humira, meaning it’s not identical to AbbVie’s product but has proved in clinical trials that it works just as well.
But an ongoing patent dispute looks likely to forestall Amjevita’s launch.
About the Author Reprints
